+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment of advanced gastric cancer with paclitaxel and cisplatin +- hematopoetic growth factor support

Treatment of advanced gastric cancer with paclitaxel and cisplatin +- hematopoetic growth factor support

Onkologie 23(Sonderheft 7): 62

(PDF emailed within 1 workday: $29.90)

Accession: 035980861

Download citation: RISBibTeXText

Related references

A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Japanese Journal of Clinical Oncology 40(4): 369-372, 2010

Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. British Journal of Cancer 95(8): 1005-1012, 2006

Pharmacoeconomic analysis of advanced non-small cell lung cancer treatment with docetaxel-cisplatin, paclitaxel-cisplatin and paclitaxel-carboplatin. European Journal of Cancer 37(Supplement 6): S233-S234, 2001

Weekly cisplatin-epirubicin-paclitaxel (PET) with granulocyte-colony stimulating factor support versus tri-weekly epirubicin-paclitaxel in locally advanced breast cancer: Final comprehensive and subgroup analysis of a SICOG phase III study. Journal of Clinical Oncology 24(18_suppl): 572-572, 2016

Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX). Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(10): 1453-1456, 2005

Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. Oncology Reports 21(2): 523-529, 2009

Efficacy and feasibility of paclitaxel and cisplatin combination chemotherapy for the treatment of 5-flurouracil (5-FU), doxorubicin refractory advanced gastric cancer. Journal of Clinical Oncology 26(15_suppl): 15674-15674, 2016

Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. Journal of Clinical Oncology 19(4): 1088-1095, 2001

Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. European Journal of Cancer 49(17): 3616-3624, 2014

Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. Cancer ChemoTherapy and Pharmacology 76(2): 397-408, 2015

Weekly cisplatin - epirubicin - paclitaxel with G-CSF support vs triweekly epirubicin-paclitaxel in advanced breast cancer A SICOG phase III trial. European Journal of Cancer 37(Supplement 6): S151-S152, 2001

Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. European Journal of Cancer 62: 103-111, 2017

Treatment of patients with advanced ovarian cancer with cisplatin/paclitaxel or carboplatin/paclitaxel - An interim analysis of the ago study protocol ovar-3. European Journal of Cancer 35(SUPPL 4): S231, Sept, 1999

Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics 20(7): 485-497, 2002

Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. American Journal of Cancer Research 6(10): 2345-2350, 2016